Form 4: Coeptis Therapeutics Holdings CTO Reports Stock Transaction

Sentiment:

Insider Transaction (Form 4)


Jeffery Keeslar Harris, Chief Technology Officer of Coeptis Therapeutics Holdings, Inc., reported multiple transactions in common stock on September 24, 2026.

Summary

  • Option exercise/conversion: acquired 12,444 Common Stock on September 24, 2026; holds 12,444 after (Direct).
  • Option exercise/conversion: disposed of 12,444 Restricted Stock Units on September 24, 2026; holds 37,334 after (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Jeffery Keeslar Harris — Officer (Chief Technology Officer)

DateTransactionSecuritySharesPriceValueHeld After
2026-09-24Option exercise/conversionCommon Stock12,444——12,444
2026-09-24Option exercise/conversionRestricted Stock Units12,444——37,334

Key Dates

DateDescription
2026-09-24Option exercise/conversion (12,444 shares)
2026-09-24Option exercise/conversion (12,444 shares)

Keywords

insider transaction, Form 4, ZSQR, Z Squared Inc., neutral, Jeffery Keeslar Harris

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.